Haibu Pharmaceutical has once again been awarded the title of "Top 20 Chinese Pharmaceutical R&D Companies".

　　The "2018 Annual China Pharmaceutical Industry Most Influential List Release Conference and the 11th China (Jinan) Pharmaceutical Industry Development Summit Forum" organized by the China Federation of Industry and Commerce Pharmaceutical Chamber was held from June 3 to 5, 2019, where 13 major awards were announced, including the Top 100 Chinese Pharmaceutical Industries of 2018, the Top 50 Growing Companies in the Chinese Pharmaceutical Industry, and the Top 20 Chinese Pharmaceutical R&D Companies.

　　As a comprehensive pharmaceutical R&D institution covering raw materials, drug formulation development, and clinical trial services, Beijing Haibu Pharmaceutical Technology Co., Ltd. has been awarded the title of "Top 20 Chinese Pharmaceutical R&D Companies" for two consecutive years.

　　Haibu Pharmaceuticals' selection as one of the "Top 20 Chinese Pharmaceutical R&D Companies" is attributed to the collective efforts of all colleagues and the recognition and support from partners. The company will further enhance its R&D skills and innovative technology applications, serving customers with a more rigorous research attitude and more efficient technology transfer capabilities.

　　[Introduction to Haibu Pharmaceuticals]

　　Beijing Haibu Pharmaceutical Technology Co., Ltd. was established in April 2005 (stock code: 836438) and is a high-tech enterprise engaged in the full industry chain of chemical drug research and development, production, and sales. The company's main business includes pharmaceutical and clinical CRO services, R&D of high-end raw materials and pharmaceutical intermediates, related registration, custom production, as well as research on chemical drug formulations and MAH business. The developed products cover multiple fields such as anti-tumor, anti-depression, cardiovascular diseases, digestive system disorders, respiratory system issues, etc.

　　In China, it has obtained over 60 clinical trial approvals for drugs and more than ten new drug certificates and drug registration approvals. More than ten series of high-end raw materials and intermediate products have achieved commercial production and are marketed globally.

　　The company is committed to optimizing innovative synthesis processes for chemical drugs. It has achieved a series of excellent results in innovative technology applications such as efficient asymmetric catalysis, enzyme catalysis, continuous flow reaction technology, challenging crystal forms and process technology patents, small molecule structural modifications etc., having applied for over ten related invention patents with ten granted.

　　[Cooperation Information]

　　Business Cooperation: Chen Zhutuo Phone: 18010182349 Email: chenzhutuo@hopelife.cn

　　API Cooperation: Yu Fuqiang Phone: 15010704183 Email: yufuqiang@hopelife.cn